A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

Study identifier:CIN-107-123

ClinicalTrials.gov identifier:NCT05432167

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

Medical condition

Uncontrolled Hypertension

Phase

Phase 2

Healthy volunteers

No

Study drug

CIN-107, Placebo

Sex

All

Actual Enrollment

194

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 29 Apr 2022
Primary Completion Date: 02 May 2024
Study Completion Date: 02 May 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria